Skip to main content
SpringerLink
Log in

Imaging After Neoadjuvant Therapy

  • Chapter
  • First Online:
Textbook of Pancreatic Cancer

Abstract

Response assessment with diagnostic cross-sectional imaging remains difficult after neoadjuvant therapy in pancreatic cancer. Imaging correlates of tumour transformation under neoadjuvant therapy are discussed in this chapter, together with efforts in research to overcome the specific challenges of response evaluation. So far, better understanding of histopathologic changes after neoadjuvant therapy have not translated into applicable imaging criteria for defining response and selecting surgical candidates. Currently, patients with non-metastatic borderline resectable and locally advanced pancreatic ductal adenocarcinoma are brought to exploratory laparotomy in the absence of overt radiologic progression after neoadjuvant therapy. Imaging research, apart from testing morphologic criteria, is focused on defining robust functional imaging parameters for response. This chapter highlights the current role of imaging and addresses topics of future investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans DB, George B, Tsai S. Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22:3409–13.

    PubMed  Google Scholar 

  2. Sugimoto M, Takahashi N, Farnell MB. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: a propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120:976.

    PubMed  Google Scholar 

  3. Unno M, Hata T, Motoi F. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today. 2019;49(4):295–9.

    PubMed  Google Scholar 

  4. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833–46.

    PubMed  PubMed Central  Google Scholar 

  5. Sadot E, Doussot A, O’Reilly EM, Lowery MA, Goodman KA, Do RK, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512–21.

    PubMed  PubMed Central  Google Scholar 

  6. Mokdad AA, Minter RM, Zhu H. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515–22.

    PubMed  Google Scholar 

  7. Van Tienhoven GV, Versteijne E, Suker M, Groothuis KBC, Busch OR, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018;36:LBA4002. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4002.

    Article  Google Scholar 

  8. Miyasaka Y, Ohtsuka T, Kimura R, Matsuda R, Mori Y, Nakata K, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery. Ann Surg Oncol. 2019;26:1528–34.

    PubMed  Google Scholar 

  9. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    CAS  PubMed  Google Scholar 

  10. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782.

    PubMed  PubMed Central  Google Scholar 

  11. Schorn S, Demir IE, Reyes CM, Saricaoglu C, Samm N, Schirren R, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - a systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96–106.

    CAS  PubMed  Google Scholar 

  12. Scheufele F, Hartmann D, Friess H. Treatment of pancreatic cancer - neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:32.

    PubMed  PubMed Central  Google Scholar 

  13. Katz MH. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.

    PubMed  Google Scholar 

  14. Isaji S, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.

    PubMed  Google Scholar 

  15. Siddiqui N, Vendrami CL, Chatterjee A, Miller FH. Advanced MR imaging techniques for pancreas imaging. Magn Reson Imaging Clin N Am. 2018;26(3):323–44.

    PubMed  Google Scholar 

  16. Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34(2-3):121–8.

    PubMed  Google Scholar 

  17. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.

    CAS  PubMed  Google Scholar 

  18. Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012;136(1):100–9.

    PubMed  Google Scholar 

  19. Kalimuthu SN, Serra S, Dhani N, Chetty R, et al. The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes. J Clin Pathol. 2016;69:463–71.

    CAS  PubMed  Google Scholar 

  20. Lafaro KJ, Melstrom LG. The paradoxical web of pancreatic cancer tumor microenvironment. Am J Pathol. 2019;189(1):44–57.

    PubMed  PubMed Central  Google Scholar 

  21. Sherman WH, Hecht E, Leung D, Chu K. Predictors of response and survival in locally advanced adenocarcinoma of the pancreas following neoadjuvant GTX with or without radiation therapy. Oncologist. 2018;23(1):4–e10.

    CAS  PubMed  Google Scholar 

  22. Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36(3):409–17.

    PubMed  PubMed Central  Google Scholar 

  23. Chatterjee D, Rashid A, Wang H, Katz MH, Wolff RA, Varadhachary GR, et al. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012;36(4):552–9.

    PubMed  PubMed Central  Google Scholar 

  24. Naito Y, Ishikawa H, Sadashima E, Okabe Y, Takahashi K, Kawahara R, et al. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: pathological local invasion and microvessel invasion analysis. Mol Clin Oncol. 2019;11(3):225–33.

    PubMed  PubMed Central  Google Scholar 

  25. Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16(1):28–37.

    PubMed  Google Scholar 

  27. Rombouts SJ, Walma MS, Vogel JA, van Rijssen LB, Wilmink JW, Mohammad NH, et al. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2016;23(13):4352–60.

    PubMed  PubMed Central  Google Scholar 

  28. Baliyan V, Kordbacheh H, Parakh A, Kambadakone A, et al. Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol. 2018;43:435–44.

    Google Scholar 

  29. Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O’Reilly EM, et al. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15(1):18.

    Google Scholar 

  30. Xia BT, Fu B, Wang J, Kim Y, Ahmad SA, Dhar VK, et al. Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol. 2017;115(4):376–83.

    CAS  PubMed  Google Scholar 

  31. Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, et al. Imaging-based biomarkers: changes in the tumour interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018;124(8):1701–9.

    CAS  PubMed  Google Scholar 

  32. Del Chiaro M, Søreide K. Trials and tribulations of neoadjuvant therapy in pancreatic cancer. Br J Surg. 2018;105(11):1387–9.

    PubMed  Google Scholar 

  33. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015;44(4):515–21.

    CAS  PubMed  Google Scholar 

  34. Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Cassinotto C, Cortade J, Belleannée G, Lapuyade B, Terrebonne E, Vendrely V, et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol. 2013;82(4):589–93.

    PubMed  Google Scholar 

  36. Ferrone C, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12–7.

    PubMed  Google Scholar 

  37. Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2017;27:3104–16.

    PubMed  Google Scholar 

  38. Beleù A, Calabrese A, Rizzo G, Capelli P, Bellini N, Caloggero S. Preoperative imaging evaluation after downstaging of pancreatic ductal adenocarcinoma: a multi-center study. Cancers (Basel). 2019;11(2):E267. https://doi.org/10.3390/cancers11020267.

    Article  CAS  Google Scholar 

  39. Cassinotto C, Mouries A, Lafourcade JP, Terrebonne E, Belleannée G, Blanc JF, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant CRT. Radiology. 2014;273(1):108–16.

    PubMed  Google Scholar 

  40. Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733–40.

    PubMed  Google Scholar 

  41. Somers I, Bipat S. Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT. Eur Radiol. 2017;27:3408–35.

    PubMed  PubMed Central  Google Scholar 

  42. Ganeshan B, Miles KA. Quantifying tumour heterogeneity with CT. Cancer Imaging. 2013;13:140–9.

    PubMed  PubMed Central  Google Scholar 

  43. Lubner MG, Stabo N, Lubner SJ, del Rio AM, Song C, Halberg RB, et al. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumour heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging. 2015;40(7):2331–7.

    PubMed  Google Scholar 

  44. Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ, et al. CT texture analysis: definitions, applications, biologic correlates, and challenges. Radiographics. 2017;37(5):1483–503.

    PubMed  Google Scholar 

  45. Cheng SH, Cheng YJ, Jin ZY, Xue HD, et al. Unresectable pancreatic ductal adenocarcinoma: role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019;113:188–97.

    PubMed  Google Scholar 

  46. Summers RM. Texture analysis in radiology: does the emperor have no clothes? Abdom Radiol. 2017;42(2):342–5.

    Google Scholar 

  47. Yamashita R, Perrin T, Chakraborty J, Chou JF, Horvat N, Koszalka MA, et al. Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation. Eur Radiol. 2019;30:195.

    PubMed  PubMed Central  Google Scholar 

  48. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with DW-MRI. J Magn Reson Imaging. 2010;32(1):2–16.

    PubMed  PubMed Central  Google Scholar 

  49. Amodeo S, Rosman AS, Desiato V, et al. MRI-based apparent diffusion coefficient for predicting pathologic response of rectal cancer after neoadjuvant therapy: systematic review and meta-analysis. AJR Am J Roentgenol. 2018;211(5):W205–W16.

    PubMed  Google Scholar 

  50. ACRIN 6698 Trial Team and I‑SPY 2 Trial Investigators, Partridge SC, Zhang Z, Newitt DC, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial. Radiology. 2018;289(3):618–27.

    Google Scholar 

  51. Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, et al. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 2014;7:644–9.

    PubMed  PubMed Central  Google Scholar 

  52. Okada KI, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, et al. Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma. J Hepatobil Pancreat Sci. 2017;24(3):161–8.

    Google Scholar 

  53. Okada KI, Kawai M, Hirono S, Kojima F, Tanioka K, Terada M, et al. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Langenbeck’s Arch Surg. 2020;405(1):23–33.

    Google Scholar 

  54. Dalah E, Erickson B, Oshima K, Feng MU, Greenson JK, Hussain HK, et al. Correlation of ADC with pathological treatment response for radiation therapy of pancreatic cancer. Transl Oncol. 2018;11(2):391–8.

    PubMed  PubMed Central  Google Scholar 

  55. Nishiofuku H, Tanaka T, Marugami N, Sho M, Akahori T, Nakajima Y, et al. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur Radiol. 2016;26:1835–42.

    PubMed  Google Scholar 

  56. Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Eßwein MR, Erkan M, et al. Co-clinical assessment of tumor cellularity in pancreatic cancer. Clin Cancer Res. 2017;23(6):1461–70.

    CAS  PubMed  Google Scholar 

  57. Iima M, Le Bihan D. Clinical intravoxel incoherent motion and diffusion MR imaging: past, present, and future. Radiology. 2016;278(1):13–32.

    PubMed  Google Scholar 

  58. Le Bihan D. What can we see with IVIM MRI? NeuroImage. 2019;187:56–67.

    PubMed  Google Scholar 

  59. Ma C, Li Y, Wang L, Wang Y, Zhang Y, Wang H, et al. Intravoxel incoherent motion DWI of the pancreatic adenocarcinomas: monoexponential and biexponential apparent diffusion parameters and histopathological correlations. Cancer Imaging. 2017;17(1):12.

    PubMed  PubMed Central  Google Scholar 

  60. De Robertis R, Cardobi N, Ortolani S, Tinazzi Martini P, Stemmer A, et al. Intravoxel incoherent motion diffusion-weighted MR imaging of solid pancreatic masses: reliability and usefulness for characterization. Abdom Radiol. 2019;44(1):131–9.

    Google Scholar 

  61. Klauss M, Lemke A, Grünberg K, Simon D, Re TJ, Wente MN, et al. Intravoxel incoherent motion MRI for the differentiation between mass forming chronic pancreatitis and pancreatic carcinoma. Investig Radiol. 2011;46(1):57–63.

    Google Scholar 

  62. Klaassen R, Gurney-Champion OJ, Engelbrecht MRW, Stoker J, Wilmink JW, Besselink MG, et al. Evaluation of six diffusion-weighted MRI models for assessing effects of neoadjuvant chemoradiation in pancreatic cancer patients. Int J Radiat Oncol Biol Phys. 2018;102(4):1052–62.

    PubMed  Google Scholar 

  63. Kurosawa J, Tawada K, Mikata R, Ishihara T, Tsuyuguchi T, Saito M, et al. Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer. J Magn Reson Imaging. 2015;42(6):1532–7.

    PubMed  Google Scholar 

  64. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Version 2.2017. J Natl Compr Cancer Netw. 2017;15(8):1028–61.

    Google Scholar 

  65. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68.

    PubMed  Google Scholar 

  66. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Medical University Innsbruck, Innsbruck, Austria

    Eva-Maria Gassner, Paulina Poskaite & Werner Jaschke

Authors
  1. Eva-Maria Gassner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paulina Poskaite
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Werner Jaschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva-Maria Gassner .

Editor information

Editors and Affiliations

  1. Stavanger University Hospital, The University of Bergen, Bergen, Norway

    Kjetil Søreide

  2. Chirurgie (VTT), Innsbruck Medical University, Innsbruck, Tirol, Austria

    Stefan Stättner

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gassner, EM., Poskaite, P., Jaschke, W. (2021). Imaging After Neoadjuvant Therapy. In: Søreide, K., Stättner, S. (eds) Textbook of Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-53786-9_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53786-9_29

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53785-2

  • Online ISBN: 978-3-030-53786-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation